Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination of five drugs**: caffeine, warfarin, omeprazole, metoprolol, and midazolam. Each drug has a distinct mechanism of action: - **Caffeine** is a central nervous system stimulant that antagonizes adenosine receptors, increasing alertness. - **Warfarin** is a vitamin K antagonist anticoagulant that inhibits vitamin K epoxide reductase to prevent clotting. - **Omeprazole** is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase in gastric parietal cells. - **Metoprolol** is a selective beta-1 adrenergic receptor antagonist used primarily to lower blood pressure and treat heart conditions. - **Midazolam** is a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, producing sedative and anxiolytic effects. This combination is not marketed as a single product and is primarily encountered in research contexts as a probe cocktail to study drug metabolism and pharmacokinetic interactions involving the cytochrome P450 system. Clinical use of all five drugs together is highly unusual and may present safety concerns due to interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + warfarin + omeprazole + metoprolol + midazolam.